Auberger P, Sonthonnax S, Peyron J F, Mari B, Fehlmann M
INSERM U210, Faculte de Medecine, Nice, France.
Immunology. 1990 Aug;70(4):547-50.
Interleukin-2 (IL-2) production by activated Jurkat T cells was markedly delayed when these cells were treated with low concentrations of the chymotryptic-type protease inhibitor N-alpha-p-tosyl-L-phenylalanine chloromethylketone (TPCK). This increased lag time observed in the presence of TPCK directly correlates with the interaction of the inhibitor with a unique 42,000 molecular weight (MW) serine protease, which can be labelled with [3H]DFP, and was not due to an intracellular accumulation of a non-mature form of IL-2 nor to a non-specific inhibition of overall protein synthesis. The results presented in this report indicate that a 42,000 MW chymotryptic-like serine protease is required for IL-2 production by activated Jurkat T cells.
当用低浓度的胰凝乳蛋白酶型蛋白酶抑制剂N-α-对甲苯磺酰-L-苯丙氨酸氯甲基酮(TPCK)处理活化的Jurkat T细胞时,这些细胞产生白细胞介素-2(IL-2)的过程明显延迟。在TPCK存在下观察到的这种延长的滞后时间与该抑制剂与一种独特的42,000分子量(MW)丝氨酸蛋白酶的相互作用直接相关,该丝氨酸蛋白酶可用[3H]DFP标记,并且不是由于IL-2非成熟形式的细胞内积累,也不是由于对整体蛋白质合成的非特异性抑制。本报告中的结果表明,活化的Jurkat T细胞产生IL-2需要一种42,000 MW的类胰凝乳蛋白酶丝氨酸蛋白酶。